CanBas Valuation

Is 4575 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 4575 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 4575's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 4575's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 4575?

Key metric: As 4575 is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for 4575. This is calculated by dividing 4575's market cap by their current book value.
What is 4575's PB Ratio?
PB Ratio	5.4x
Book	JP¥3.20b
Market Cap	JP¥16.95b

4575 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	n/a
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does 4575's PB Ratio compare to its peers?

The above table shows the PB ratio for 4575 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	5.5x
4588 Oncolys BioPharma	8.4x	n/a	JP¥16.0b
4598 Delta-Fly Pharma	6.2x	n/a	JP¥4.7b
4883 Modalis Therapeutics	3.2x	n/a	JP¥8.0b
190A Chordia Therapeutics	4x	n/a	JP¥16.9b
4575 CanBas	5.4x	n/a	JP¥17.0b

Price-To-Book vs Peers: 4575 is good value based on its Price-To-Book Ratio (5.4x) compared to the peer average (5.5x).

Price to Book Ratio vs Industry

How does 4575's PB Ratio compare vs other companies in the JP Biotechs Industry?

1 Company	Price / Book	Estimated Growth	Market Cap
2342 Transgenic Group	0.6x	n/a	US$21.32m

No more companies available in this PB range

1 Company		Estimated Growth	Market Cap

No more companies

Price-To-Book vs Industry: 4575 is expensive based on its Price-To-Book Ratio (5.4x) compared to the JP Biotechs industry average (3.6x).

Price to Book Ratio vs Fair Ratio

What is 4575's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

4575 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	5.4x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 4575's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Shionogi

JP¥1.8t

Engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan.

4507

JP¥2,094.50

-2.1%

-10.9%

Tsumura

JP¥368.9b

Manufactures and sells pharmaceutical products from crude drugs derived from plants and other natural products in Japan and internationally.

4540

JP¥4,858.00

1.2%

76.3%

ASKA Pharmaceutical HoldingsLtd

JP¥57.7b

Through its subsidiaries, engages in the pharmaceutical, animal health, and hormone testing businesses in Japan.

4886

JP¥2,036.00

-2.2%

13.1%